> Cell Genesys of South San Francisco has arranged $75 million in financing from Kingsbridge Capital over the next three years. Report
> The FDA has given GenVec approval to expand a mid-stage trial of TNFerade for pancreatic cancer into a Phase II/III study. GenVec also announced that Kingsbridge Capital will provide $30 million in financing over three years. Report
> Wisconsin is devoting $9 million to a new research facility for pandemic flu viruses like bird flu. The 20,000 square-foot facility will be built in University Research Park in Madison. Report
> Pharmacopeia is expanding its collaboration deal with Neurocrine Biosciences. Report
> DuPont will cut 1,500 jobs and close facilities in Europe as part of its restructuring of its performance coatings division. Report
> Avant Immunotherapeutics has amended an agreement to accelerate a $40 million milestone payment. Release
> Nastech has entered into a multi-compound agreement with Novo Nordisk. Release
And Finally… As Sweden and Denmark were added to the list of countries confirming bird flu, HHS Secretary Michael Leavitt repeated warnings that the virus was likely to wind up on American shores in a matter of months. Article